A new drug may be the first to give relief to sufferers of pseudobulbar affect. Nov. 4, 2010— -- When David Diehl, a third-generation family farmer, became a paraplegic five days after an ...
This article is sponsored by Otsuka America Pharmaceutical, Inc. In long-term care environments, it’s not uncommon for site staff including nurses, administrators, physical therapists, physicians and ...
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization of a treatment for pseudobulbar affect (PBA) in adults ...
“Understanding Pseudobulbar Affect,” the inaugural publication of the new Insights & Implications in Gerontology series from The Gerontological Society of America, addresses an often overlooked or ...
November 2, 2010 — The US Food and Drug Administration (FDA) has approved dextromethorphan HBr and quinidine sulfate 20 mg/10 mg capsules (Nuedexta; Avanir Pharmaceuticals, Inc) as the first treatment ...
Although pseudobulbar affect (PBA)—which is characterized by uncontrollable and exaggerated or inappropriate laughing or crying—typically occurs in people with certain neurological conditions or brain ...
CA_092018_Feature-2_Image Pseudobulbar affect is a significant national health issue in the United States, with approximately 2 million individuals affected. Pseudobulbar affect is characterized by ...
Uncontrolled laughing or crying might indicate pseudobulbar affect (PBA), a neurological condition causing involuntary emotional outbursts unrelated to actual feelings. Frequently linked to stroke, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback